The Journal of Allergy and Clinical Immunology: In Practice
Clinical CommunicationsAssessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air
Section snippets
Acknowledgments
The MASK study group: I. Agache, X. Basagaña, A. Bédard, K. C. Bergmann, C. Bindslev-Jensen, H. Blain, S. Bosnic-Anticevich, I. Bosse, L. P. Boulet, L. Brussino, P. Camargos, G. W. Canonica, P. Carreiro-Martins, V. Cardona, L. Cecchi, D. Chu, E. Costa, A. A. Cruz, J. da Silva, G. De Vries, P. Devillier, W. J. Fokkens, J. F. Fontaine, J.-M. Fuentes-Pérez, B. Gemicioğlu, T. Haahtela, Y. R. Huerta-Villalobos, J. C. Ivancevich, M. Jutel, I. Kaidashev, M. Khaitov, L. Klimek, H. Kraxner, P. Kuna, V.
References (9)
- et al.
The Allergic Rhinitis Control Test questionnaire is valuable in guiding step-down pharmacotherapy treatment of allergic rhinitis
J Allergy Clin Immunol Pract
(2019) - et al.
Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma
Allergy
(2010) - et al.
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
Clin Transl Allergy
(2019) - et al.
Validity, reliability and responsiveness of daily monitoring visual analogue scales in MASK-air®
Clin Transl Allergy
(2021)
Cited by (0)
No funding was received for this work.
Conflicts of interest: J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach, other from KYomed-Innov, and personal fees from Purina. J. A. Fonseca reports personal fees from AstraZeneca and Viatris, and grants and personal fees from Mundipharma, The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to the paper.